article thumbnail

Analyzing biosimilar market dynamics in different patient populations

Drug Patent Watch

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%

article thumbnail

The Competitive Edge of Biosimilars

DrugBank

Biosimilars  Biosimilars, while highly similar to their reference biopharmaceuticals, offer distinct advantages that position them as preferred therapeutic options in many cases. This is because biosimilars are not new drugs but highly similar versions of already approved therapies with established safety and efficacy profiles.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of biosimilar insulin products in diabetes care

Drug Patent Watch

The Future of Diabetes Care: How Biosimilar Insulin Products Are Revolutionizing Treatment As we continue to navigate the ever-evolving landscape of diabetes care, one thing is clear: innovation is key. And when it comes to insulin therapy, a game-changing trend is emerging: biosimilar insulin products.

article thumbnail

Unsuccessful Regulatory Filings for Biosimilar Approval: A Comprehensive Review

Drug Patent Watch

A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs.

article thumbnail

The Evolution of Medical Benefit Contracting: How Pharma Can Prepare

Drug Channels

Saket discusses market access and contracting strategies for medical benefit products when pharmacy benefit biosimilar therapies launch. Today’s guest post comes from Saket Patel, Consultant, Advisory Services at MMIT. He then describes how to automate formulary and medical policies to protect manufacturers from overpayment.

article thumbnail

COMMERCIALIZATION AND LICENSE AGREEMENT FOR PROPOSED BIOSIMILAR CURRENTLY IN PHASE 3 WITH THE POTENTIAL TO TREAT MODERATE TO SEVERE RHEUMATOID ARTHRITIS

The Pharma Data

Biogen enters into a commercialization and license agreement to develop, manufacture and commercialize BAT1806, a proposed biosimilar referencing ACTEMRA ® (tocilizumab). Biosimilars have the potential to enable greater access to marketed biologic therapies while generating cost savings and healthcare sustainability.

article thumbnail

FDA APPROVES RIABNI™ (RITUXIMAB-ARRX), A BIOSIMILAR TO RITUXAN® (RITUXIMAB), FOR ADULTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS?

The Pharma Data

New Indication for Amgen’s Fifth FDA-approved Biosimilar. “Our fully integrated portfolio of innovative and biosimilar medicines for inflammatory diseases reinforces our commitment to providing patients with high-quality and affordable treatment options that deliver substantial value to our healthcare system.”